Anaveon to present first clinical data from the Phase I/II study of ANV419 at the AACR Annual Meeting 2022
Basel, 9 March, 2022 – Anaveon, a clinical-stage immuno-oncology company, today announced that it will present first clinical data from the ongoing Phase I/II study of ANV419, a powerful and selective interleukin-2 (IL-2) agonist in patients with solid tumors, in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, Louisana, April 8 to April 13, 2022. Abstracts will be available online starting 1:00 pm ET on Friday, April 8, 2022.
Details of the poster presentation are:
Abstract Title: “ANV419, an IL-2R-beta-gamma targeted antibody-IL-2 fusion protein, induces selective effector cell proliferation in patients with progressed cancer”
Presentation Number: CT140
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 35
Poster Board Number: 7
Authors: Elena Garralda, Guzman Alonso, Juanita Lopez, Heinz Läubli, Emiliano Calvo, Christoph Huber, Nicole Egli, Aswathy Nair, Kirsten Richter, Sangeetha Jetwa, Silvio Costanzo, Christoph Bucher
Date/Time: April 11, 2022 at 1:30 pm - 5:00 pm ET
Anaveon is undertaking a Phase I/II study to evaluate the safety, dosing and clinical activity of its lead program, ANV419, a powerful and selective interleukin-2 (IL-2) agonist in patients with solid tumors. The Company is pursuing multiple parallel Phase II programs in order to explore the full therapeutic potential of ANV419. In addition, Anaveon continues its work in developing follow-on compounds to expand on the success of ANV419 by delivering the IL-2 agonist to tumor fighting cells and thus expand the therapeutic potential into less immunogenic tumors. Alongside this, the Company is building on its cytokine engineering expertise with preclinical-stage programs harnessing the power of cytokines for therapeutic purposes.
Tel: +44 (0)7818 430877
Anaveon is a clinical-stage biopharmaceutical company, based in Switzerland, that develops biologics to modulate the function of cytokines and provide substantial therapeutic benefit to cancer patients. Our vision is to develop novel immune therapies benefiting patients suffering from a wide variety of diseases with immune pathology. For further information please visit the Company’s website at: www.anaveon.com.